Collectively, our data suggest that dual blockade of ER and PRMT5 can effectively suppress tumor growth of ER+/RB-deficient breast cancer, thus providing the basis for testing this therapeutic combination in patients with this refractory breast cancer genotype. The gene discussed is ESR1; the disease is neoplasm.